Bank of New York Mellon’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-14,638
| Closed | -$132K | – | 4312 |
|
|
2025
Q4 | $132K | Buy |
+14,638
| New | +$109K | ﹤0.01% | 4086 |
|
|
2025
Q2 | – | Sell |
-175,112
| Closed | -$201K | – | 4276 |
|
|
2025
Q1 | $201K | Sell |
175,112
-1,841
| -1% | -$3.16K | ﹤0.01% | 3885 |
|
|
2024
Q4 | $388K | Buy |
176,953
+651
| +0.4% | +$1.48K | ﹤0.01% | 3651 |
|
|
2024
Q3 | $384K | Sell |
176,302
-54,291
| -24% | -$125K | ﹤0.01% | 3642 |
|
|
2024
Q2 | $533K | Buy |
230,593
+84,984
| +58% | +$353K | ﹤0.01% | 3554 |
|
|
2024
Q1 | $801K | Sell |
145,609
-10,302
| -7% | -$47.1K | ﹤0.01% | 3267 |
|
|
2023
Q4 | $385K | Sell |
155,911
-8,241
| -5% | -$78.3K | ﹤0.01% | 3697 |
|
|
2023
Q3 | $5.7M | Buy |
164,152
+15,450
| +10% | +$534K | ﹤0.01% | 2249 |
|
|
2023
Q2 | $4.88M | Buy |
148,702
+57,396
| +63% | +$1.98M | ﹤0.01% | 2338 |
|
|
2023
Q1 | $3.06M | Sell |
91,306
-19,081
| -17% | -$742K | ﹤0.01% | 2563 |
|
|
2022
Q4 | $3.62M | Buy |
110,387
+29,942
| +37% | +$887K | ﹤0.01% | 2525 |
|
|
2022
Q3 | $2.81M | Buy |
80,445
+30,153
| +60% | +$668K | ﹤0.01% | 2619 |
|
|
2022
Q2 | $615K | Buy |
50,292
+26,050
| +107% | +$389K | ﹤0.01% | 3462 |
|
|
2022
Q1 | $329K | Buy |
24,242
+6,688
| +38% | +$89.4K | ﹤0.01% | 3967 |
|
|
2021
Q4 | $349K | Buy |
+17,554
| New | +$333K | ﹤0.01% | 4011 |
|
Other funds holding VTYX
Bank of New York Mellon's VTYX Position: Q1 2026 in Review
Bank of New York Mellon sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 14,638 shares — an estimated $132K sold.
Bank of New York Mellon first reported a position in VTYX in Q4 2021 and held it in 15 quarters. The position peaked at $5.7M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Bank of New York Mellon reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Bank of New York Mellon sold 14,638 Ventyx Biosciences shares in Q1 2026, an estimated $132K.
- Bank of New York Mellon first reported a position in Ventyx Biosciences in Q4 2021 and held it in 15 quarters.
- Bank of New York Mellon's Ventyx Biosciences position peaked at $5.7M in Q3 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Bank of New York Mellon's 13F filing for Q1 2026, filed 5 May 2026.